At present, clinical genetic testing for SLC9A6 mutations is available through multigene panels for epilepsy and neurodevelopmental disorders or next-generation sequencing platforms in many developed countries, but access remains limited in low-resource settings. The gene discussed is SLC9A6; the disease is neurodevelopmental disorder.